Acinetobacter Pneumonia Therapeutics Market Analysis

Route of Administration (Parenteral, Oral, Inhalation)

The parenteral segment is set to capture around 73.5% acinetobacter pneumonia therapeutics market share by the end of 2037.  The segment’s rapid growth is owed to administrations of higher drug concentrations in severe Acinetobacter pneumonia cases. The method involves delivering medications directly to the bloodstream using intravenous (IV) or intramuscular (IM) injections, ensuring rapid drug absorption. In September 2019, the U.S. FDA approved Lefamulin that can be administered in oral and intravenous formulations to treat community acquired bacterial pneumonia. With the rising cases of MDR Acinetobacter strains, demand for IV antibiotics to quickly reach therapeutic levels in critically ill patients is driving the parenteral segment. For instance, in July 2024, Paratek Pharmaceuticals announced positive top-line efficacy from the postmarketing data of Nuzyra (Omadacycline) for patients with moderate to severe community-acquired bacterial pneumonia.

The oral segment in the treatment of Acinetobacter pneumonia is poised to increase its market share by the end of the forecast period. The segment’s growth is owed to ease of administration in moderate cases and in patients transitioning from home care to hospital care. Oral administration is comparatively more patient-friendly and reduces the requirements of an extended hospital stay. The development of new orally administered drug formulations to treat Acinetobacter pneumonia cases is poised to maintain the growth of the segment by cementing its position in early patient care. In December 2020, a study published in the National Library of Medicine highlighted new antibiotics for bacterial pneumonia to be administered orally such as omadacycline, solithromycin, and lefamulin.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacies segment is projected to witness robust growth and increase acinetobacter pneumonia therapeutics market share by the end of the forecast period. The segment’s growth is attributed to the large footfall of patients and its role in providing antibiotics and treatment for bacterial pneumonia. The segment is a major distribution channel for critically ill patients, as most severe cases occur in hospital settings; hence, the demand for effective treatment is concentrated at hospital pharmacies. Hospital pharmacies stock oral and parenteral antibiotics for bacterial pneumonia care, boosting the market’s growth as major distributors send their antibiotic stocks to the pharmacies due to increasing sales.

Our in-depth analysis of the Acinetobacter pneumonia therapeutics market includes the following segments: